Part No: P144Issued year: 2016File size: 0.6mbFile type: pdf
The ability to extract a broad range of different drugs from a biological matrix allows for the expedited analysis of a patient sample using LC-MS/MS. Typically small molecules are extracted from matrices like urine based on their polarities. A fast and reliable sample preparation method that could be implemented to extract drugs of different polarities from urine could be used as a screening tool to quickly identify the presence of illicit drugs in patient samples using LC-MS-MS.
This poster demonstrates the utility of supported liquid extraction for the extraction of over 30 different acidic, basic and neutral drugs in urine prior to LC-MS/MS.
Part No: AN815Issued year: 2014File size: 1.52mbFile type: pdf
The method described in this application note achieves high recoveries of THC and an extended suite of common metabolites in oral fluid from Quantisal (Immunalysis) oral fluid collection devices.
This application note describes effective and efficient
ISOLUTE SLE+ protocols optimized for sample loading volumes of either 300 μL or 800 μL. The simple sample preparation procedure delivers clean extracts and analyte recoveries greater than 64% with RSDs of <10% for all analytes.
Part No: PPS443Issued year: 2017File size: 2.31mbFile type: pdf
Analysis of drug panels in urine samples can be challenging, and the trend towards larger panels including multiple drug classes compounds the issues faced during method development.
This white paper examines a number of aspects of sample preparation, and their impact on the success of subsequent LC-MS/MS analysis of broad urine panels.
Section 1 examines the applicability of various sample preparation techniques: supported liquid extraction, reverse phase SPE and mixed-mode SPE, to the various classes of drugs extracted. In addition, hydrolysis approaches: enzyme type and protocol used (time, temperature), are compared.
Mixed-mode reverse phase/cation exchange SPE is widely used for extraction of basic drug classes from urine, but the inclusion of drugs and metabolites that exhibit ‘non-typical’ functionality within urine panels can be problematic. Section 2 examines the impact of various parameters (interference wash strength, elution solvent composition) on analyte retention, elution and extract cleanliness with particular focus on zwitterionic (gabapentin, pregabalin) and non-ionic (carisoprodol, meprobamate) drugs.
Part No: P112Issued year: 2014File size: 1.4mbFile type: pdf
This poster demonstrates the extraction of a range of drugs of abuse from oral fluid, collected with common collection devices, prior to UPLC-MS/MS analysis. The target analyte list includes benzodiazepines, z drugs, amphetamines, cathinones, opiates, cocaine, buprenorphine, PCP, THC-COOH, fentanyl and ketamine.
Part No: P087Issued year: 2014File size: 0.94mbFile type: pdf
This poster describes the extraction of a range of drugs of abuse (including barbiturates, THC and metabolites, benzodiazepines, z drugs, amphetamines,cathinones, opiates, cocaine, buprenorphine, PCP, fentanyl and ketamine) from oral fluid using supported liquid extraction (ISOLUTE SLE+) columns prior to GC-MS and LC-MS/MS analysis.
Part No: AN841Issued year: 2015File size: 0.82mbFile type: pdf
This application note describes the extraction of 11-nor-9-carboxy-THC from a urine matrix, prior to GC/MS analysis.
Carboxy-THC is the primary metabolite of THC, a key indicator of illicit marijuana usage. In urine, ~80% of the carboxy-THC metabolite is present in the form of its glucuronide metabolite. Therefore, to effectively quantify the THC-COOH, urine is hydrolyzed before extraction. This application note describes optimized extraction of urine samples prepared by either enzymatic or base hydrolysis.
Part No: AN875Issued year: 2017File size: 3.36mbFile type: pdf
This application note describes the extraction, using ISOLUTE SLE+ supported liquid extraction columns, of 49 drugs of abuse from whole blood, prior to UPLC-MS/MS analysis.
High, reproducible drug recoveries are achieved, with sub ng/mL LOQs for most analytes. The method is easily automated using Biotage® Extrahera.
Part No: AN809Issued year: 2014File size: 1.3mbFile type: pdf
This application note describes the simultaneous extraction of THC and its major metabolites, including 11-nor-9-carboxy-Δ9-THC glucuronide, from urine using supported liquid extraction (ISOLUTE® SLE+ in both plate and column formats) prior to analysis by LC-MS/MS.
Part No: AN867Issued year: 2016File size: 1.28mbFile type: pdf
This application note describes the extraction, using ISOLUTE SLE+ supported liquid extraction columns, of THC, THCA and Carboxy-THC from oral fluid matrix collected using the NeoSal device, prior to GC/MS analysis.
Part No: AN840Issued year: 2015File size: 0.7mbFile type: pdf
This application note describes the extraction of Δ9-THC, 11-hydroxy- Δ9-THC and 11-nor-9-carboxy-THC from whole blood matrix, prior to GC/MS analysis.
An extremely simple sample pre-treatment and extraction method is employed to extract the parent THC and main metabolites from complex whole blood matrix, delivering high, reproducible analyte recoveries.
Part No: AN819Issued year: 2014File size: 1.54mbFile type: pdf
This application note describes the extraction of THC, THCA and Carboxy-THC from oral fluid matrix collected using the Intercept Oral Fluid Drug Test Kit (Orasure Technologies), prior to GC/MS analysis.
Part No: AN822Issued year: 2014File size: 1.57mbFile type: pdf
This application note describes the extraction of THC, THCA and Carboxy-THC from oral fluid matrix collected using the Quantisal™ (Immunalysis) device, prior to GC/MS analysis.
The ISOLUTE SLE+ protocol is optimized for 400 μL and 1 mL sample capacity formats. The simple sample preparation procedure delivers clean extracts and analyte recoveries greater than 75% with RSDs lower than 10% for all analytes.
Part No: P165Issued year: 2017File size: 0.32mbFile type: pdf
This poster evaluates 3 different sample preparation approaches (ISOLUTE SLE+, EVOLUTE EXPRESS ABN, EVOLUTE EXPRESS CX) for extraction of large multi-drug urine panels.
Each approach is assessed in terms of suitability for extraction of analytes with different different properties (pka, LogP etc).